Stepan Company (SCL) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Stepan Company produces and sells intermediate chemicals used in consumer and industrial applications. The business is organized into three reportable segments: Surfactants (72% of YTD sales), Polymers (25% of YTD sales), and Specialty Products (3% of YTD sales).
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales | $590.3M | $546.8M | $1,778.2M | $1,654.7M |
| Gross Profit | $71.0M | $75.7M | $218.4M | $215.5M |
| Operating Income | $21.8M | $23.9M | $68.0M | $62.8M |
| Net Income | $10.8M | $23.6M | $41.9M | $47.0M |
| Diluted EPS | $0.47 | $1.03 | $1.83 | $2.05 |
| Operating Cash Flow (YTD) | $87.9M (2025) vs $93.8M (2024) | |||
| Total Debt | $655.5M (Sep 30, 2025) vs $625.4M (Dec 31, 2024) | |||
| Cash & Equivalents | $118.5M (Sep 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 Net Sales increased 8% year-over-year, driven by higher average selling prices (+$30.8M) and favorable foreign currency translation (+$8.6M), partially offset by a 2% decline in Surfactant sales volume.
- Profitability Decline: Q3 Net Income dropped 54% to $10.8M. This was primarily due to a significant increase in the effective tax rate (34.4% in Q3 2025 vs. negative 10.7% in Q3 2024) caused by a tax provision adjustment and the non-recurrence of a favorable GILTI event from the prior year.
- Segment Performance:
- Surfactants: Operating income fell 40% ($15.7M) due to lower unit margins driven by start-up costs at the new Pasadena, Texas facility and higher oleochemical raw material costs.
- Specialty Products: Operating income surged 158% ($9.6M) due to order timing fluctuations in the pharmaceutical business.
- Polymers: Operating income decreased 8% ($14.1M) due to lower average selling prices passing through lower raw material costs.
- Corporate Expenses: Decreased 17% year-over-year, largely due to the non-recurrence of a $3.3M charge related to a criminal social engineering fraud event in Q3 2024.
Guidance, Outlook, and Risks
- Capital Expenditures: Management estimates total 2025 capital expenditures will range between $118.0M and $123.0M.
- Dividends: The company paid $0.385 per share in Q3 2025. Unrestricted retained earnings available for dividends were $267.9M as of September 30, 2025.
- Tax Legislation: The 2025 U.S. Tax Act (H.R.1) was signed into law on July 4, 2025. Management does not currently believe provisions regarding bonus depreciation, R&D expensing, or interest deduction limitations will have a material impact on 2025 results.
- Environmental & Legal Contingencies:
- Accrued environmental and legal losses range from $19.4M to $44.7M. The company accrued an additional $1.8M in Q2 2025 for remediation at the Elwood, Illinois (Millsdale) facility.
- In Q3 2025, the company paid a $1.1M USEPA civil penalty for FIFRA violations related to biocide products, recovering $0.5M from third parties.
- Asset Disposal: The company announced the sale of its Philippines manufacturing assets (Surfactants segment), with closing expected in Q4 2025.
Investor Verification Checklist
- Tax Rate Volatility: Verify the sustainability of the effective tax rate given the one-time adjustments in Q3 2025 and the impact of the new 2025 U.S. Tax Act.
- Surfactant Margins: Monitor the impact of the new Pasadena, Texas alkoxylation facility start-up costs on gross margins in subsequent quarters.
- Environmental Accruals: Review the range of potential environmental liabilities ($19.4M - $44.7M) and the specific risks associated with the Millsdale and Maywood sites.
- Debt Covenants: Confirm continued compliance with the minimum interest coverage ratio (3.50:1) and net leverage ratio (3.50:1) covenants.
- Foreign Currency Impact: Assess the sensitivity of future earnings to USD fluctuations, particularly against the Mexican peso and Brazilian real, which negatively impacted YTD sales.